# Hematologic Malignancies

> **NIH CA P30** · FRED HUTCHINSON CANCER CENTER · 2026 · $401,412

## Abstract

PROJECT SUMMARY
Blood cancers afflict children and adults and are life-threatening. The Hematologic Malignancies (HM) Program
is dedicated to understanding the causes of blood cancers and developing successful gene, drug, and cellular
treatment options to improve the quality of life and survival of patients. These goals are accomplished through
four major aims: 1) create a deeper understanding of the biologic basis of hematological malignancies; 2)
enhance our knowledge of hematopoietic stem cell (HSC) biology and our capabilities for gene therapy of
hematological malignancies; 3) develop novel non-transplant treatments; and 4) improve the availability, safety,
and efficacy of hematopoietic cell transplantation. These complementary and intersecting aims bring together
multidisciplinary expertise in hematology, immunology, genomics, clinical trial design/implementation,
computation, and biostatistics. Synergy across the research aims is achieved through close collaborations with
patients and providers, interactions with COE, CRTEC, and PED, and a well-integrated network of clinical and
research faculty. The HM Program currently has 105 members from all three Consortium institutions. Broad
expertise of clinicians and clinical and basic scientists provide a deep skill set to successfully accomplish the
program’s aims. The scientific goals are supported by the complementary expertise of Program Co-Leaders Dr.
Fred Appelbaum (non-transplant) and Dr. Effie Petersdorf (transplant) and by Associate Program Leaders Dr.
Janis Abkowitz (leukemia biology) and Dr. Hans-Peter Kiem (gene therapy). The structural organization of faculty
with a disease (adult leukemia; pediatric leukemia; myeloma; myelodysplasia; lymphoma) and research (myeloid
stem cell biology; gene therapy; radio-immunotherapy; hematopoietic cell transplantation; long-term follow-up)
focus enhances collaborations within and across the program. Program members currently have $38.7M in
research funding of which $12

## Key facts

- **NIH application ID:** 11303342
- **Project number:** 5P30CA015704-51
- **Recipient organization:** FRED HUTCHINSON CANCER CENTER
- **Principal Investigator:** FREDERICK  APPELBAUM
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $401,412
- **Award type:** 5
- **Project period:** 1997-01-01T00:00:00 → 2029-12-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11303342

## Citation

> US National Institutes of Health, RePORTER application 11303342, Hematologic Malignancies (5P30CA015704-51). Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/grant/nih/11303342. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*